
Dr Andree Bates discusses the importance of diagnosing value constraints in AI initiatives within pharma organizations.
Many pharma and life science organisations have been investing in AI for years: pilots across commercial, medical, regulatory, and R&D, innovation labs, steering committees, vendor spend, and genuine effort from smart teams. And yet the same story keeps showing up in boardrooms: ROI is unclear, adoption is patchy, and leaders struggle to explain how all the AI activity connects to strategic goals. In this solo episode, Dr Andree Bates steps into “The Diagnostic Room” to explain why this happens, and why it’s usually not a technology, talent, or speed issue. It’s a diagnosis issue: organisations often haven’t identified what is actually constraining value, so they end up executing hard on the wrong problem. Dr Andree shares a real example from a mid-sized pharma company that believed its AI programme was failing due to lack of velocity. On the surface, it was a reasonable hypothesis. But a focused diagnostic revealed three hidden structural blockers: unclear decision rights for scaling pilots into production, fragmented data ownership preventing access to the best datasets, and incentive misalignment where the people expected to adopt AI tools were not rewarded for the…
Host: Dr Andree Bates
Organizations: pharma and life science organisations, mid-sized pharma company
Explore listener stats, chart rankings, contacts and more on the AI For Pharma Growth podcast page.